Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin

Lü, Qian; Wang, Yangyang; Wang, Qiuhong; Tang, Lina; Yang, Xianchao; Dun, Shuo; Zou, Li‐Ping

doi:10.1016/j.seizure.2022.05.010

Cited by 10 publications

(23 citation statements)

References 12 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one person reported having a fever within a week after receiving the second dose and did not experience a seizure. Some studies have reported on the attitudes, coverage, and general side effects of COVID-19 vaccines in people with epilepsy [3] , [10] , [11] , [13] , [14] , but few have focused on epilepsy-related adverse effects [4] , [12] , [15] . In some cases, obtaining a vaccinated cohort was difficult [4] , [12] , making the conclusions less robust.…”

Section: Discussionmentioning

confidence: 99%

“…Some studies have reported on the attitudes, coverage, and general side effects of COVID-19 vaccines in people with epilepsy [3] , [10] , [11] , [13] , [14] , but few have focused on epilepsy-related adverse effects [4] , [12] , [15] . In some cases, obtaining a vaccinated cohort was difficult [4] , [12] , making the conclusions less robust. In the vaccinated group, 16 patients (7.50%) experienced seizure worsening, and all seizures in this study were habitual.…”

Section: Discussionmentioning

confidence: 99%

“…One recent study reported that only pre-vaccine seizure frequency was associated with seizure worsening in vaccinated patients, which suggests that uncontrolled epilepsy could affect post-vaccine seizure frequency rather than be a direct effect of the vaccine [15] . Other studies failed to identify the potential risks of seizure worsening after vaccination due to small sample sizes [4] , [5] , [12] .…”

Section: Discussionmentioning

confidence: 99%

“…A mass immunization program is considered the best method of slowing the pandemic, and the COVID-19 vaccine is safe for the vast majority of people [3] , [4] , [5] , [6] , though there are some post-vaccination cases of demyelinating diseases, cerebral venous sinus thrombosis, and seizures among healthy people without epilepsy [7] , [8] , [9] . While there are a limited number of PWE in studies with COVID-19 vaccines [4] , [5] , [10] , [11] , [12] and a lack of emphasis on seizure worsening, the International League Against Epilepsy (ILAE) still recommended that PWE should get vaccinated. However, many PWE have been hesitant to get vaccinated [3] , [10] , [11] , [12] , [13] , [14] , [15] .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

COVID-19 vaccination hesitancy and safety among adult people with epilepsy in eastern China

Wang¹,

Yang

et al. 2023

Epilepsy & Behavior

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 vaccination hesitancy and safety among adult people with epilepsy in eastern China

Wang¹,

Yang

et al. 2023

Epilepsy & Behavior

View full text Add to dashboard Cite

“…Most of study on everolimus in patients TSC‐related epilepsy from out of China had comparable seizure control, 16–20 but one randomized controlled trial on sirolimus did not find significantly reduced seizure frequency in children with TSC and intractable epilepsy 21 (Table 1). Furthermore, the inactivated COVID‐19 vaccine was well tolerated and safe in children with TSC‐related epilepsy treated with sirolimus, which was confirmed by the follow‐up of 44 patients who completed the two‐dose inactivated COVID‐19 vaccine in China 22 …”

Section: Mtor Inhibitors In Patients With Tsc‐related Epilepsymentioning

confidence: 67%

Progress of clinical research studies on tuberous sclerosis complex‐related epilepsy in China

Liu

Chen

Zhai

et al. 2022

Acta Neuro Scandinavica

View full text Add to dashboard Cite

Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome, with 75.6%–83.5% and 54.1% patients presenting with epilepsy and drug‐resistant epilepsy (DRE), respectively. Clinical studies on TSC, particularly surgical interventions, have achieved rapid and substantial progress. The TSC‐Task Force Committee of the China Association Against Epilepsy (CAAE‐TFTSC) was founded in 2012, and annual academic conferences on the surgical treatment of TSC‐related epilepsy have been held since 2013. ‘China experts' consensus on surgical treatment of TSC‐related epilepsy’ was published in 2019. This review focuses on surgical treatment, including resective surgery, neuromodulations, corpus callosotomy and mini‐invasive ablations, as well as studies on phenotype, genotype and anti‐seizure therapies of mammalian target of rapamycin inhibitor, vigabatrin and ketogenic diet in patients with TSC‐related DRE in China.

show abstract

Safety and adverse events following COVID‐19 vaccination among people with epilepsy: A cross‐sectional study

et al. 2022

View full text Add to dashboard Cite

Objective Epilepsy is a non‐communicable disease costing a massive burden globally. It is known that there is increased prevalence of morbidity and mortality following COVID‐19 infection among people with epilepsy (PWE). However, there is limited information about the adverse events following COVID‐19 immunization among PWE. Hence, this study aimed to assess the safety and adverse events following immunization (AEFI) of various COVID‐19 vaccines among PWE from our centre, focusing on neurological AEFI. Methods This cross‐sectional study recruited 120 adult PWE from the Neurology Clinic of the Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Consent‐taking was conducted via synchronous or asynchronous approaches, followed by a phone call interview session. The interview collected socio‐demographic information, epilepsy‐related variables, and vaccination‐related variables. Univariate analysis and multiple logistic regression analysis were done to confirm factors associated with the AEFI of COVID‐19 vaccination. Results Among all types of COVID‐19 vaccines, most of the PWE received the Cominarty® COVID‐19 vaccination (52.5%). Overall, local AEFI was the quickest to develop, with an average onset within a day. PWE with normal body mass index (BMI) had a higher risk of developing both local and systemic AEFI compared to those underweight and obese PWE (OR: 15.09, 95% CI 1.70–134.28, P = 0.02). Significance COVID‐19 vaccines are safe for PWE. AEFI among PWE are similar to those of the general population following COVID‐19 vaccination. Therefore, clinicians should encourage PWE to take COVID‐19 vaccines.

show abstract

Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin

Cited by 10 publications

References 12 publications

COVID-19 vaccination hesitancy and safety among adult people with epilepsy in eastern China

COVID-19 vaccination hesitancy and safety among adult people with epilepsy in eastern China

Progress of clinical research studies on tuberous sclerosis complex‐related epilepsy in China

Safety and adverse events following COVID‐19 vaccination among people with epilepsy: A cross‐sectional study

Contact Info

Product

Resources

About